Does Rallies show Form 4 insider transactions for OCGN?

Yes. Rallies tracks OCGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OCGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OCGN. It does not provide personalized investment advice.

OCGN (Ocugen, Inc. Common Stock) Stock Analysis - Insider Trades

Ocugen, Inc. Common Stock (OCGN) is a publicly traded Healthcare sector company. As of May 21, 2026, OCGN trades at $1.36 with a market cap of $453.62M and a P/E ratio of 0.00. OCGN moved +5.38% today. Year to date, OCGN is -6.21%; over the trailing twelve months it is +67.90%. Its 52-week range spans $0.52 to $2.73. Analyst consensus is strong buy with an average price target of $11.57. Rallies surfaces OCGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OCGN stock inside the company?

Recent OCGN insider activity includes Fernandes Prabhavathi bought 10.00K, Castillo Kirsten bought 25.00K, Zhang Junge bought 200.28K, Musunuri Shankar sold 100.00K, and Musunuri Shankar sold 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OCGN Key Metrics

Key financial metrics for OCGN
Metric	Value
Price	$1.36
Market Cap	$453.62M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$2.73
52-Week Low	$0.52
Volume	2.05K
Avg Volume	0
Revenue (TTM)	$4.41M
Net Income	$-67.85M
Gross Margin	0.00%

Recent OCGN Insider Trades

Fernandes Prabhavathi bought 10.00K (~$9.10K) on Nov 26, 2024.
Castillo Kirsten bought 25.00K (~$22.85K) on Nov 22, 2024.
Zhang Junge bought 200.28K (~$100.00K) on Jun 14, 2023.
Musunuri Shankar sold 100.00K (~$108.00K) on Feb 16, 2023.
Musunuri Shankar sold 100.00K (~$128.00K) on Jan 17, 2023.

Latest OCGN News

Ocugen closes $130M 6.75% convertible notes sale, extends runway to 2028 — May 14, 2026
Ocugen posts $19.2M Q1 loss, raises $115M to extend cash runway — May 5, 2026
Ocugen Launches $115M Convertible Note Offering with $15M Upsize Option — May 4, 2026
Ocugen to Present Modifier Therapy Updates at April Conferences, BLA Submission Plans — Apr 23, 2026
Ocugen’s Gene Therapy Cuts Geographic Atrophy Growth by 46% — Apr 10, 2026

OCGN Analyst Consensus

7 analysts cover OCGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.57.

Common questions about OCGN

Who is trading OCGN stock inside the company?: Recent OCGN insider activity includes Fernandes Prabhavathi bought 10.00K, Castillo Kirsten bought 25.00K, Zhang Junge bought 200.28K, Musunuri Shankar sold 100.00K, and Musunuri Shankar sold 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OCGN?: Yes. Rallies tracks OCGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OCGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OCGN. It does not provide personalized investment advice.